Literature DB >> 6091538

Comparison of itraconazole and ketoconazole in the treatment of experimental candidal vaginitis.

J D Sobel, G Muller.   

Abstract

Comparison of itraconazole (R51,211) and ketoconazole in the treatment of experimental candidal vaginitis in rats on schedules of 3 and 5 days revealed significantly superior results with itraconazole at all dosages (1.0 to 7.5 mg/kg) studied, but was particularly evident at 1.0 and 2.5 mg/kg. A single 25-mg/kg dose of itraconazole was as effective as 5 daily 5-mg/kg doses of itraconazole.

Entities:  

Mesh：

Substances：

Year:  1984        PMID： 6091538      PMCID： PMC284134          DOI： 10.1128/AAC.26.2.266

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  3 in total

1.  Cure and relapse with antifungal therapy.

Authors:  F C Odds
Journal:  Proc R Soc Med       Date:  1977

2.  Treatment of vaginal candidiasis with ketoconazole, a new, orally active, antimycotic.

Authors:  M P Bisschop; J M Merkus; H Scheygrond; J Van Cutsem; A van de Kuy
Journal:  Eur J Obstet Gynecol Reprod Biol       Date:  1979-08       Impact factor: 2.435

3.  Comparison of ketoconazole, Bay N7133, and Bay L9139 in the treatment of experimental vaginal candidiasis.

Authors:  J D Sobel; G Muller
Journal:  Antimicrob Agents Chemother       Date:  1983-09       Impact factor: 5.191
  3 in total
  8 in total

1.  High-dose itraconazole in the treatment of severe mycoses.

Authors:  P K Sharkey; M G Rinaldi; J F Dunn; T C Hardin; R J Fetchick; J R Graybill
Journal:  Antimicrob Agents Chemother       Date:  1991-04       Impact factor: 5.191

2.  Ocular toxicity of experimental intravitreal itraconazole.

Authors:  J A Schulman; G A Peyman; J Dietlein; R Fiscella
Journal:  Int Ophthalmol       Date:  1991-01       Impact factor: 2.031

Review 3.  Overview of medically important antifungal azole derivatives.

Authors:  R A Fromtling
Journal:  Clin Microbiol Rev       Date:  1988-04       Impact factor: 26.132

4.  Evaluation of Bay R 3783 in rodent models of superficial and systemic candidiasis, meningeal cryptococcosis, and pulmonary aspergillosis.

Authors:  R F Hector; E Yee
Journal:  Antimicrob Agents Chemother       Date:  1990-03       Impact factor: 5.191

5.  Itraconazole vs amphotericin B: in vitro comparative evaluation of the minimal inhibitory concentration (MIC) against clinically isolated yeasts.

Authors:  G Lombardi; G Gramegna; C Cavanna; G Poma; E Marangoni; G Michelone
Journal:  Mycopathologia       Date:  1989-04       Impact factor: 2.574

6.  Hormonal factors in vaginal candidiasis in rats.

Authors:  O S Kinsman; A E Collard
Journal:  Infect Immun       Date:  1986-09       Impact factor: 3.441

7.  Placebo-controlled trial of itraconazole for treatment of acute vaginal candidiasis.

Authors:  G E Stein; N Mummaw
Journal:  Antimicrob Agents Chemother       Date:  1993-01       Impact factor: 5.191

8.  Activity of UK-49,858, a bis-triazole derivative, against experimental infections with Candida albicans and Trichophyton mentagrophytes.

Authors:  K Richardson; K W Brammer; M S Marriott; P F Troke
Journal:  Antimicrob Agents Chemother       Date:  1985-05       Impact factor: 5.191
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.